Agenus Announces Stock Symbol to Revert Back to AGEN
October 11 2011 - 10:10AM
Agenus Inc. (Nasdaq:AGEND), a developer of therapeutic vaccines for
cancer and infectious diseases, today announced that in response to
the Company's request, NASDAQ will remove the fifth character "D"
from the Company's stock symbol and the Company's stock symbol will
revert back to AGEN on Wednesday, October 12, 2011, at the open of
the market. The fifth character "D" was appended to the Company's
stock symbol to designate that the Company's common stock was
trading on a post-reverse split basis.
The Company anticipates receipt of the NASDAQ compliance
determination following the anticipated 10th consecutive day of
closing above $1.00 per share, or after October 14, 2011.
About Agenus
Agenus Inc. is a biotechnology company working to develop
treatments for cancers and infectious diseases. The company is
focused on immunotherapeutic products based on strong platform
technologies with multiple product candidates advancing through the
clinic, including several product candidates that have advanced
into late-stage clinical trials through corporate partners. For
more information, please visit www.agenusbio.com.
The Agenus logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8187
Forward-Looking Statement
This press release contains forward-looking statements,
including statements regarding clinical trial activities, the
publication of data, and the potential application of the Company's
product candidates in the prevention and treatment of diseases.
These forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include, among others, the factors
described under the Risk Factors section of our Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission for the
period ended June 30, 2011. Agenus cautions investors not to place
considerable reliance on the forward-looking statements contained
in this release. These statements speak only as of the date of this
document, and Agenus undertakes no obligation to update or revise
the statements. All forward-looking statements are expressly
qualified in their entirety by this cautionary statement. Agenus'
business is subject to substantial risks and uncertainties,
including those identified above. When evaluating Agenus' business
and securities, investors should give careful consideration to
these risks and uncertainties.
CONTACT: Jonae R. Barnes, 617-818-2985
Agenus Inc. (MM) (NASDAQ:AGEND)
Historical Stock Chart
From Oct 2024 to Oct 2024
Agenus Inc. (MM) (NASDAQ:AGEND)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Agenus Inc. (MM) (NASDAQ): 0 recent articles
More Agenus Inc. News Articles